All In Biotech

Drug Trial Radar · NCT07357220

A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases

A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of AK112 in Combination With VG2025 in Patients With Advanced Colorectal Cancer With Liver Metastases

Last checked: Nov 19, 2026Latest source record: Jan 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

72

Planned (sponsor's estimate)

Start

Mar 2, 2026

Primary completion

Feb 28, 2027

Study completion Feb 28, 2028

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
Collaborators
Shanghai Virogin Biotech Co., Ltd.
First posted
Jan 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open-label, multicenter, phase Ib/II study of AK112 in combination with VG2025 for advanced colorectal cancer with liver metastases.

Conditions

  • Colorectal Cancer With Hepatic Metastases

Interventions

  • VG2025Biological

    Recommended Phase II Dose, Intratumoral Injection, Q4W

  • AK112Drug

    20mg/kg, ivgtt, Q2W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants experiencing dose-limiting toxicities (DLTs)Time frame: From Day 1 to Day 28 after the first tumour vaccine was administrated in safety run-in cohorts
  2. Number of participants with adverse events (AEs) and severityTime frame: From ICF up to 30 days after last study treatment
  3. Objective Response Rate (ORR)Time frame: Time Frame: Up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital, Zhejiang University School of Medicine,No. 79, Qingchun Road, Shangcheng District, Hangzhou City, Zhejiang Province

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.